{"id":1335,"date":"2018-02-05T16:35:26","date_gmt":"2018-02-05T16:35:26","guid":{"rendered":"https:\/\/www.groupactionlawyers.co.uk\/blog\/?p=1335"},"modified":"2018-02-05T16:37:25","modified_gmt":"2018-02-05T16:37:25","slug":"class-4-drug-alert-kyowa-kirin-bleo-kyowa-powder-solution","status":"publish","type":"post","link":"https:\/\/www.groupactionlawyers.co.uk\/blog\/class-4-drug-alert-kyowa-kirin-bleo-kyowa-powder-solution","title":{"rendered":"Class 4 drug alert for Kyowa Kirin Bleo-Kyowa Powder Solution"},"content":{"rendered":"<p>The Medicines and Healthcare products Regulatory Agency (MHRA) has issued a drug alert for the Bleo-Kyowa powder over a &#8216;minor&#8217; defect being reported.<\/p>\n<p>The agency cites glass particles being detected in a batch of the medicine back in April 2017.<\/p>\n<p>Hospitals, pharmacies and other healthcare providers are requested to take caution in using the Bleomycin Sulphate powder that acts as an anticancer chemotherapy medicine.<br \/>\n<!--more--><br \/>\n<strong>The medicine is used for:<\/strong><\/p>\n<div class=\"well\">\n<ul>\n<li>Skin cancer<\/li>\n<li>Thyroid cancer<\/li>\n<li>Lung cancer<\/li>\n<li>Bladder cancer<\/li>\n<li>Hodgkin\u2019s disease<\/li>\n<li>Testicular tumours or cancer<\/li>\n<li>Malignant effusions<\/li>\n<\/ul>\n<\/div>\n<p><strong>Only one batch is reportedly affected in the medical alert: 97B210.<\/strong> <\/p>\n<p>The packets contain 10 doses and were first distributed in November 2017, and are due to expire on 31<sup>st<\/sup> August 2020. The marketing authorisation holder is conducting an investigation into the quality defect. New batches are reportedly unaffected and meet current quality requirements, and will therefore continue to be supplied to the U.K.<\/p>\n<p>In the meantime, healthcare professionals are to take additional measures before using Bleo-Kyowa powders belonging to the alerted batch:<\/p>\n<div class=\"well\">\n<ul class=\"blog-list\">\n<li>Follow the recommended steps for preparing the powder<\/li>\n<li>Carefully inspect the product under a bright light<\/li>\n<li>If particulate or bits of glass can be seen, the product must not be used. The vial is to be retained and quarantined from the rest of the stock. The clinician is required to inform the marketing authorisation holder that they possess a defective pack<\/li>\n<li>If no particulate or bits of glass can be seen, the use of a standard 5 micron (5\u00b5m) filter needle must be used to withdraw the product from the vial before administrating it into the patient. The needle should filter out the glass particles that aren&#8217;t easily visible<\/li>\n<\/ul>\n<\/div>\n<p>Glass particles in medicine of-course carry a very clear danger for patients. Sharp edges aside, it&#8217;s a foreign material that should not be inside our bloodstream at all. If the particulates are injected into the blood stream through the vein, they may be carried to the heart and then the lungs via the pulmonary arteries, causing damage.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>The Medicines and Healthcare products Regulatory Agency (MHRA) has issued a drug alert for the Bleo-Kyowa powder over a &#8216;minor&#8217; defect being reported. The agency cites glass particles being detected in a batch of the medicine back in April 2017. Hospitals, pharmacies and other healthcare providers are requested to take caution in using the Bleomycin &hellip; <a href=\"https:\/\/www.groupactionlawyers.co.uk\/blog\/class-4-drug-alert-kyowa-kirin-bleo-kyowa-powder-solution\" class=\"more-link\">Continue reading <span class=\"screen-reader-text\">Class 4 drug alert for Kyowa Kirin Bleo-Kyowa Powder Solution<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":1340,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[5],"tags":[20],"class_list":["post-1335","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-medical","tag-mhra"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Class 4 Drug Alert For Kyowa Kirin Bleo-Kyowa Powder Solution<\/title>\n<meta name=\"description\" content=\"Glass particles have been detected in a batch of the Bleo-Kyowa powder medicine. The Medicines and Healthcare products Regulatory Agency (MHRA) has issued a &#039;minor&#039; defect alert for the drug since its been reported.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.groupactionlawyers.co.uk\/blog\/class-4-drug-alert-kyowa-kirin-bleo-kyowa-powder-solution\" \/>\n<meta property=\"og:locale\" content=\"en_GB\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Class 4 Drug Alert For Kyowa Kirin Bleo-Kyowa Powder Solution\" \/>\n<meta property=\"og:description\" content=\"Glass particles have been detected in a batch of the Bleo-Kyowa powder medicine. The Medicines and Healthcare products Regulatory Agency (MHRA) has issued a &#039;minor&#039; defect alert for the drug since its been reported.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.groupactionlawyers.co.uk\/blog\/class-4-drug-alert-kyowa-kirin-bleo-kyowa-powder-solution\" \/>\n<meta property=\"og:site_name\" content=\"Group Action Lawyers\" \/>\n<meta property=\"article:published_time\" content=\"2018-02-05T16:35:26+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2018-02-05T16:37:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/i2.wp.com\/www.groupactionlawyers.co.uk\/blog\/wp-content\/uploads\/mhra-alert-large-min.png?fit=1200%2C680&ssl=1\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"680\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:image\" content=\"https:\/\/i0.wp.com\/www.groupactionlawyers.co.uk\/blog\/wp-content\/uploads\/mhra-alert-large-min.png?fit=1200%2C680&ssl=1\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Estimated reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.groupactionlawyers.co.uk\\\/blog\\\/class-4-drug-alert-kyowa-kirin-bleo-kyowa-powder-solution#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.groupactionlawyers.co.uk\\\/blog\\\/class-4-drug-alert-kyowa-kirin-bleo-kyowa-powder-solution\"},\"author\":{\"name\":\"Admin\",\"@id\":\"https:\\\/\\\/www.groupactionlawyers.co.uk\\\/blog\\\/#\\\/schema\\\/person\\\/3c954adf13d2913933b2069fbd6df781\"},\"headline\":\"Class 4 drug alert for Kyowa Kirin Bleo-Kyowa Powder Solution\",\"datePublished\":\"2018-02-05T16:35:26+00:00\",\"dateModified\":\"2018-02-05T16:37:25+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.groupactionlawyers.co.uk\\\/blog\\\/class-4-drug-alert-kyowa-kirin-bleo-kyowa-powder-solution\"},\"wordCount\":342,\"commentCount\":0,\"image\":{\"@id\":\"https:\\\/\\\/www.groupactionlawyers.co.uk\\\/blog\\\/class-4-drug-alert-kyowa-kirin-bleo-kyowa-powder-solution#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/i0.wp.com\\\/www.groupactionlawyers.co.uk\\\/blog\\\/wp-content\\\/uploads\\\/mhra-alert-min.png?fit=725%2C250&ssl=1\",\"keywords\":[\"mhra\"],\"articleSection\":[\"Medical\"],\"inLanguage\":\"en-GB\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/www.groupactionlawyers.co.uk\\\/blog\\\/class-4-drug-alert-kyowa-kirin-bleo-kyowa-powder-solution#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.groupactionlawyers.co.uk\\\/blog\\\/class-4-drug-alert-kyowa-kirin-bleo-kyowa-powder-solution\",\"url\":\"https:\\\/\\\/www.groupactionlawyers.co.uk\\\/blog\\\/class-4-drug-alert-kyowa-kirin-bleo-kyowa-powder-solution\",\"name\":\"Class 4 Drug Alert For Kyowa Kirin Bleo-Kyowa Powder Solution\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.groupactionlawyers.co.uk\\\/blog\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.groupactionlawyers.co.uk\\\/blog\\\/class-4-drug-alert-kyowa-kirin-bleo-kyowa-powder-solution#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.groupactionlawyers.co.uk\\\/blog\\\/class-4-drug-alert-kyowa-kirin-bleo-kyowa-powder-solution#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/i0.wp.com\\\/www.groupactionlawyers.co.uk\\\/blog\\\/wp-content\\\/uploads\\\/mhra-alert-min.png?fit=725%2C250&ssl=1\",\"datePublished\":\"2018-02-05T16:35:26+00:00\",\"dateModified\":\"2018-02-05T16:37:25+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.groupactionlawyers.co.uk\\\/blog\\\/#\\\/schema\\\/person\\\/3c954adf13d2913933b2069fbd6df781\"},\"description\":\"Glass particles have been detected in a batch of the Bleo-Kyowa powder medicine. The Medicines and Healthcare products Regulatory Agency (MHRA) has issued a 'minor' defect alert for the drug since its been reported.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.groupactionlawyers.co.uk\\\/blog\\\/class-4-drug-alert-kyowa-kirin-bleo-kyowa-powder-solution#breadcrumb\"},\"inLanguage\":\"en-GB\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.groupactionlawyers.co.uk\\\/blog\\\/class-4-drug-alert-kyowa-kirin-bleo-kyowa-powder-solution\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\\\/\\\/www.groupactionlawyers.co.uk\\\/blog\\\/class-4-drug-alert-kyowa-kirin-bleo-kyowa-powder-solution#primaryimage\",\"url\":\"https:\\\/\\\/i0.wp.com\\\/www.groupactionlawyers.co.uk\\\/blog\\\/wp-content\\\/uploads\\\/mhra-alert-min.png?fit=725%2C250&ssl=1\",\"contentUrl\":\"https:\\\/\\\/i0.wp.com\\\/www.groupactionlawyers.co.uk\\\/blog\\\/wp-content\\\/uploads\\\/mhra-alert-min.png?fit=725%2C250&ssl=1\",\"width\":725,\"height\":250,\"caption\":\"mhra alert\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.groupactionlawyers.co.uk\\\/blog\\\/class-4-drug-alert-kyowa-kirin-bleo-kyowa-powder-solution#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.groupactionlawyers.co.uk\\\/blog\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Class 4 drug alert for Kyowa Kirin Bleo-Kyowa Powder Solution\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.groupactionlawyers.co.uk\\\/blog\\\/#website\",\"url\":\"https:\\\/\\\/www.groupactionlawyers.co.uk\\\/blog\\\/\",\"name\":\"Group Action Lawyers\",\"description\":\"Latest Legal News, Articles &amp; Opinions\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.groupactionlawyers.co.uk\\\/blog\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-GB\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.groupactionlawyers.co.uk\\\/blog\\\/#\\\/schema\\\/person\\\/3c954adf13d2913933b2069fbd6df781\",\"name\":\"Admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80c638f202b7125d0217e22b6b80daa614813aec57ba35fb6741bb7737941f2c?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80c638f202b7125d0217e22b6b80daa614813aec57ba35fb6741bb7737941f2c?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80c638f202b7125d0217e22b6b80daa614813aec57ba35fb6741bb7737941f2c?s=96&d=mm&r=g\",\"caption\":\"Admin\"},\"url\":\"https:\\\/\\\/www.groupactionlawyers.co.uk\\\/blog\\\/author\\\/admin\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Class 4 Drug Alert For Kyowa Kirin Bleo-Kyowa Powder Solution","description":"Glass particles have been detected in a batch of the Bleo-Kyowa powder medicine. The Medicines and Healthcare products Regulatory Agency (MHRA) has issued a 'minor' defect alert for the drug since its been reported.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.groupactionlawyers.co.uk\/blog\/class-4-drug-alert-kyowa-kirin-bleo-kyowa-powder-solution","og_locale":"en_GB","og_type":"article","og_title":"Class 4 Drug Alert For Kyowa Kirin Bleo-Kyowa Powder Solution","og_description":"Glass particles have been detected in a batch of the Bleo-Kyowa powder medicine. The Medicines and Healthcare products Regulatory Agency (MHRA) has issued a 'minor' defect alert for the drug since its been reported.","og_url":"https:\/\/www.groupactionlawyers.co.uk\/blog\/class-4-drug-alert-kyowa-kirin-bleo-kyowa-powder-solution","og_site_name":"Group Action Lawyers","article_published_time":"2018-02-05T16:35:26+00:00","article_modified_time":"2018-02-05T16:37:25+00:00","og_image":[{"width":1200,"height":680,"url":"https:\/\/i2.wp.com\/www.groupactionlawyers.co.uk\/blog\/wp-content\/uploads\/mhra-alert-large-min.png?fit=1200%2C680&ssl=1","type":"image\/png"}],"author":"Admin","twitter_card":"summary_large_image","twitter_image":"https:\/\/i0.wp.com\/www.groupactionlawyers.co.uk\/blog\/wp-content\/uploads\/mhra-alert-large-min.png?fit=1200%2C680&ssl=1","twitter_misc":{"Written by":"Admin","Estimated reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.groupactionlawyers.co.uk\/blog\/class-4-drug-alert-kyowa-kirin-bleo-kyowa-powder-solution#article","isPartOf":{"@id":"https:\/\/www.groupactionlawyers.co.uk\/blog\/class-4-drug-alert-kyowa-kirin-bleo-kyowa-powder-solution"},"author":{"name":"Admin","@id":"https:\/\/www.groupactionlawyers.co.uk\/blog\/#\/schema\/person\/3c954adf13d2913933b2069fbd6df781"},"headline":"Class 4 drug alert for Kyowa Kirin Bleo-Kyowa Powder Solution","datePublished":"2018-02-05T16:35:26+00:00","dateModified":"2018-02-05T16:37:25+00:00","mainEntityOfPage":{"@id":"https:\/\/www.groupactionlawyers.co.uk\/blog\/class-4-drug-alert-kyowa-kirin-bleo-kyowa-powder-solution"},"wordCount":342,"commentCount":0,"image":{"@id":"https:\/\/www.groupactionlawyers.co.uk\/blog\/class-4-drug-alert-kyowa-kirin-bleo-kyowa-powder-solution#primaryimage"},"thumbnailUrl":"https:\/\/i0.wp.com\/www.groupactionlawyers.co.uk\/blog\/wp-content\/uploads\/mhra-alert-min.png?fit=725%2C250&ssl=1","keywords":["mhra"],"articleSection":["Medical"],"inLanguage":"en-GB","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.groupactionlawyers.co.uk\/blog\/class-4-drug-alert-kyowa-kirin-bleo-kyowa-powder-solution#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.groupactionlawyers.co.uk\/blog\/class-4-drug-alert-kyowa-kirin-bleo-kyowa-powder-solution","url":"https:\/\/www.groupactionlawyers.co.uk\/blog\/class-4-drug-alert-kyowa-kirin-bleo-kyowa-powder-solution","name":"Class 4 Drug Alert For Kyowa Kirin Bleo-Kyowa Powder Solution","isPartOf":{"@id":"https:\/\/www.groupactionlawyers.co.uk\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.groupactionlawyers.co.uk\/blog\/class-4-drug-alert-kyowa-kirin-bleo-kyowa-powder-solution#primaryimage"},"image":{"@id":"https:\/\/www.groupactionlawyers.co.uk\/blog\/class-4-drug-alert-kyowa-kirin-bleo-kyowa-powder-solution#primaryimage"},"thumbnailUrl":"https:\/\/i0.wp.com\/www.groupactionlawyers.co.uk\/blog\/wp-content\/uploads\/mhra-alert-min.png?fit=725%2C250&ssl=1","datePublished":"2018-02-05T16:35:26+00:00","dateModified":"2018-02-05T16:37:25+00:00","author":{"@id":"https:\/\/www.groupactionlawyers.co.uk\/blog\/#\/schema\/person\/3c954adf13d2913933b2069fbd6df781"},"description":"Glass particles have been detected in a batch of the Bleo-Kyowa powder medicine. The Medicines and Healthcare products Regulatory Agency (MHRA) has issued a 'minor' defect alert for the drug since its been reported.","breadcrumb":{"@id":"https:\/\/www.groupactionlawyers.co.uk\/blog\/class-4-drug-alert-kyowa-kirin-bleo-kyowa-powder-solution#breadcrumb"},"inLanguage":"en-GB","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.groupactionlawyers.co.uk\/blog\/class-4-drug-alert-kyowa-kirin-bleo-kyowa-powder-solution"]}]},{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/www.groupactionlawyers.co.uk\/blog\/class-4-drug-alert-kyowa-kirin-bleo-kyowa-powder-solution#primaryimage","url":"https:\/\/i0.wp.com\/www.groupactionlawyers.co.uk\/blog\/wp-content\/uploads\/mhra-alert-min.png?fit=725%2C250&ssl=1","contentUrl":"https:\/\/i0.wp.com\/www.groupactionlawyers.co.uk\/blog\/wp-content\/uploads\/mhra-alert-min.png?fit=725%2C250&ssl=1","width":725,"height":250,"caption":"mhra alert"},{"@type":"BreadcrumbList","@id":"https:\/\/www.groupactionlawyers.co.uk\/blog\/class-4-drug-alert-kyowa-kirin-bleo-kyowa-powder-solution#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.groupactionlawyers.co.uk\/blog"},{"@type":"ListItem","position":2,"name":"Class 4 drug alert for Kyowa Kirin Bleo-Kyowa Powder Solution"}]},{"@type":"WebSite","@id":"https:\/\/www.groupactionlawyers.co.uk\/blog\/#website","url":"https:\/\/www.groupactionlawyers.co.uk\/blog\/","name":"Group Action Lawyers","description":"Latest Legal News, Articles &amp; Opinions","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.groupactionlawyers.co.uk\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-GB"},{"@type":"Person","@id":"https:\/\/www.groupactionlawyers.co.uk\/blog\/#\/schema\/person\/3c954adf13d2913933b2069fbd6df781","name":"Admin","image":{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/secure.gravatar.com\/avatar\/80c638f202b7125d0217e22b6b80daa614813aec57ba35fb6741bb7737941f2c?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/80c638f202b7125d0217e22b6b80daa614813aec57ba35fb6741bb7737941f2c?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/80c638f202b7125d0217e22b6b80daa614813aec57ba35fb6741bb7737941f2c?s=96&d=mm&r=g","caption":"Admin"},"url":"https:\/\/www.groupactionlawyers.co.uk\/blog\/author\/admin"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/i0.wp.com\/www.groupactionlawyers.co.uk\/blog\/wp-content\/uploads\/mhra-alert-min.png?fit=725%2C250&ssl=1","jetpack-related-posts":[{"id":406,"url":"https:\/\/www.groupactionlawyers.co.uk\/blog\/chewy-calcium-vitamin-d-tablets-being-recalled-for-impurities","url_meta":{"origin":1335,"position":0},"title":"Chewy calcium and vitamin-D tablets are being recalled for impurities","author":"Admin","date":"28th December 2016","format":false,"excerpt":"Teva U.K. Limited - a global pharmaceutical company - has recalled a batch of class 2 medicines due to a possible metal contamination. The pharmaceutical company has recently made a precautionary batch recall for a 'small number' of Evacal D3 chewable tablets. The tablets are a calcium-vitamin D supplement used\u2026","rel":"","context":"In &quot;Medical&quot;","block_context":{"text":"Medical","link":"https:\/\/www.groupactionlawyers.co.uk\/blog\/category\/medical"},"img":{"alt_text":"drugs","src":"https:\/\/i0.wp.com\/www.groupactionlawyers.co.uk\/blog\/wp-content\/uploads\/2016\/11\/drugs-recall-750x250.png?fit=750%2C250&ssl=1&resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/www.groupactionlawyers.co.uk\/blog\/wp-content\/uploads\/2016\/11\/drugs-recall-750x250.png?fit=750%2C250&ssl=1&resize=350%2C200 1x, https:\/\/i0.wp.com\/www.groupactionlawyers.co.uk\/blog\/wp-content\/uploads\/2016\/11\/drugs-recall-750x250.png?fit=750%2C250&ssl=1&resize=525%2C300 1.5x, https:\/\/i0.wp.com\/www.groupactionlawyers.co.uk\/blog\/wp-content\/uploads\/2016\/11\/drugs-recall-750x250.png?fit=750%2C250&ssl=1&resize=700%2C400 2x"},"classes":[]},{"id":849,"url":"https:\/\/www.groupactionlawyers.co.uk\/blog\/diclo-sr-75-pain-relief-tablets-class-2-recall","url_meta":{"origin":1335,"position":1},"title":"Class 2 recall for Diclo-SR 75 pain-relief tablets","author":"Admin","date":"28th July 2017","format":false,"excerpt":"A Watford-based pharmaceutical company has issued a voluntary recall for batches of Diclo-SR 75 pain relief tablets - AKA diclofenac sodium. The tablets are commonly used for pain relief and swelling for arthritis, musculoskeletal disorders, gout and pain caused by injury or minor surgery. The tablets are classified in a\u2026","rel":"","context":"In &quot;Medical&quot;","block_context":{"text":"Medical","link":"https:\/\/www.groupactionlawyers.co.uk\/blog\/category\/medical"},"img":{"alt_text":"pain relief tablets recall","src":"https:\/\/i0.wp.com\/www.groupactionlawyers.co.uk\/blog\/wp-content\/uploads\/pain-relief-tablets-recall-min.png?fit=725%2C250&ssl=1&resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/www.groupactionlawyers.co.uk\/blog\/wp-content\/uploads\/pain-relief-tablets-recall-min.png?fit=725%2C250&ssl=1&resize=350%2C200 1x, https:\/\/i0.wp.com\/www.groupactionlawyers.co.uk\/blog\/wp-content\/uploads\/pain-relief-tablets-recall-min.png?fit=725%2C250&ssl=1&resize=525%2C300 1.5x, https:\/\/i0.wp.com\/www.groupactionlawyers.co.uk\/blog\/wp-content\/uploads\/pain-relief-tablets-recall-min.png?fit=725%2C250&ssl=1&resize=700%2C400 2x"},"classes":[]},{"id":1383,"url":"https:\/\/www.groupactionlawyers.co.uk\/blog\/focus-pharmaceuticals-barcode-errors-8-medicinal-products","url_meta":{"origin":1335,"position":2},"title":"MHRA issue &#8220;Class 4&#8221; drug alert warning for Focus Pharmaceuticals after barcode errors found on 8 medicinal products","author":"Admin","date":"21st February 2018","format":false,"excerpt":"The Medicines and Healthcare Products Regulatory Agency (MHRA) issued a Class 4 (caution in use) warning over eight Focus Pharmaceutical medicinal products after a problem was found with the barcodes. The packaging fault may interfere with prescriptions as the wrong product may be identified when they're scanned. The medicines themselves\u2026","rel":"","context":"In &quot;Medical&quot;","block_context":{"text":"Medical","link":"https:\/\/www.groupactionlawyers.co.uk\/blog\/category\/medical"},"img":{"alt_text":"barcode error alert","src":"https:\/\/i0.wp.com\/www.groupactionlawyers.co.uk\/blog\/wp-content\/uploads\/barcode-error-min.png?fit=725%2C250&ssl=1&resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/www.groupactionlawyers.co.uk\/blog\/wp-content\/uploads\/barcode-error-min.png?fit=725%2C250&ssl=1&resize=350%2C200 1x, https:\/\/i0.wp.com\/www.groupactionlawyers.co.uk\/blog\/wp-content\/uploads\/barcode-error-min.png?fit=725%2C250&ssl=1&resize=525%2C300 1.5x, https:\/\/i0.wp.com\/www.groupactionlawyers.co.uk\/blog\/wp-content\/uploads\/barcode-error-min.png?fit=725%2C250&ssl=1&resize=700%2C400 2x"},"classes":[]},{"id":627,"url":"https:\/\/www.groupactionlawyers.co.uk\/blog\/carefusion-syringe-pumps-incompatible-with-any-syringe-type","url_meta":{"origin":1335,"position":3},"title":"CareFusion syringe pumps are incompatible with any syringe type","author":"Admin","date":"27th April 2017","format":false,"excerpt":"Following on from medical device alerts from the Medicines and Healthcare products Regulatory Agency (MHRA), CareFusion has made updates and replacements to the MDA\/2016\/023 Alaris syringe pumps that were at risk of having uncontrolled bolus i.e. chewed up amounts of substances from the medicine. Medical device alert 1 On 22nd\u2026","rel":"","context":"In &quot;Medical&quot;","block_context":{"text":"Medical","link":"https:\/\/www.groupactionlawyers.co.uk\/blog\/category\/medical"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/www.groupactionlawyers.co.uk\/blog\/wp-content\/uploads\/2016\/12\/medical.png?fit=725%2C250&ssl=1&resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/www.groupactionlawyers.co.uk\/blog\/wp-content\/uploads\/2016\/12\/medical.png?fit=725%2C250&ssl=1&resize=350%2C200 1x, https:\/\/i0.wp.com\/www.groupactionlawyers.co.uk\/blog\/wp-content\/uploads\/2016\/12\/medical.png?fit=725%2C250&ssl=1&resize=525%2C300 1.5x, https:\/\/i0.wp.com\/www.groupactionlawyers.co.uk\/blog\/wp-content\/uploads\/2016\/12\/medical.png?fit=725%2C250&ssl=1&resize=700%2C400 2x"},"classes":[]},{"id":517,"url":"https:\/\/www.groupactionlawyers.co.uk\/blog\/arthritis-tablets-may-adversely-affect-braille-users","url_meta":{"origin":1335,"position":4},"title":"Arthritis tablets may adversely affect users who rely solely on Braille","author":"Admin","date":"6th February 2017","format":false,"excerpt":"The Medicines and Healthcare products Regulatory Agency (MHRA) recently issued a caution relating to a drug that treats adult patients with active rheumatoid arthritis or active psoriatic arthritis. Global pharmaceutical company\u00a0Sanofi informed the medical agency of the error on the Braille on the packaging of some batches of the Arava\u2026","rel":"","context":"In &quot;Medical&quot;","block_context":{"text":"Medical","link":"https:\/\/www.groupactionlawyers.co.uk\/blog\/category\/medical"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/www.groupactionlawyers.co.uk\/blog\/wp-content\/uploads\/2016\/11\/xarelto-concerns.png?fit=725%2C250&ssl=1&resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/www.groupactionlawyers.co.uk\/blog\/wp-content\/uploads\/2016\/11\/xarelto-concerns.png?fit=725%2C250&ssl=1&resize=350%2C200 1x, https:\/\/i0.wp.com\/www.groupactionlawyers.co.uk\/blog\/wp-content\/uploads\/2016\/11\/xarelto-concerns.png?fit=725%2C250&ssl=1&resize=525%2C300 1.5x, https:\/\/i0.wp.com\/www.groupactionlawyers.co.uk\/blog\/wp-content\/uploads\/2016\/11\/xarelto-concerns.png?fit=725%2C250&ssl=1&resize=700%2C400 2x"},"classes":[]},{"id":525,"url":"https:\/\/www.groupactionlawyers.co.uk\/blog\/mirena-inserters-incorrectly-mounted-class-4-mhra-alert","url_meta":{"origin":1335,"position":5},"title":"Class 4 MHRA alert: Mirena inserters incorrectly mounted","author":"Admin","date":"14th February 2017","format":false,"excerpt":"Bayer plc, a global pharmaceutical company, has received two complaints with regards to its Mirena inserters. The complaints detail that the insertion tube was mounted inversely to the handle, and this has led to an inversion of the insertion depth scale, which may lead to incorrect insertion depth; consequently reducing\u2026","rel":"","context":"In &quot;Medical&quot;","block_context":{"text":"Medical","link":"https:\/\/www.groupactionlawyers.co.uk\/blog\/category\/medical"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/www.groupactionlawyers.co.uk\/blog\/wp-content\/uploads\/2016\/12\/medical.png?fit=725%2C250&ssl=1&resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/www.groupactionlawyers.co.uk\/blog\/wp-content\/uploads\/2016\/12\/medical.png?fit=725%2C250&ssl=1&resize=350%2C200 1x, https:\/\/i0.wp.com\/www.groupactionlawyers.co.uk\/blog\/wp-content\/uploads\/2016\/12\/medical.png?fit=725%2C250&ssl=1&resize=525%2C300 1.5x, https:\/\/i0.wp.com\/www.groupactionlawyers.co.uk\/blog\/wp-content\/uploads\/2016\/12\/medical.png?fit=725%2C250&ssl=1&resize=700%2C400 2x"},"classes":[]}],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/www.groupactionlawyers.co.uk\/blog\/wp-json\/wp\/v2\/posts\/1335","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.groupactionlawyers.co.uk\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.groupactionlawyers.co.uk\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.groupactionlawyers.co.uk\/blog\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.groupactionlawyers.co.uk\/blog\/wp-json\/wp\/v2\/comments?post=1335"}],"version-history":[{"count":5,"href":"https:\/\/www.groupactionlawyers.co.uk\/blog\/wp-json\/wp\/v2\/posts\/1335\/revisions"}],"predecessor-version":[{"id":1343,"href":"https:\/\/www.groupactionlawyers.co.uk\/blog\/wp-json\/wp\/v2\/posts\/1335\/revisions\/1343"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.groupactionlawyers.co.uk\/blog\/wp-json\/wp\/v2\/media\/1340"}],"wp:attachment":[{"href":"https:\/\/www.groupactionlawyers.co.uk\/blog\/wp-json\/wp\/v2\/media?parent=1335"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.groupactionlawyers.co.uk\/blog\/wp-json\/wp\/v2\/categories?post=1335"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.groupactionlawyers.co.uk\/blog\/wp-json\/wp\/v2\/tags?post=1335"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}